AGC Biologics to provide additional pDNA for Pifzer-BioNTech vaccine
CDMO's Germany facility will supply starting material as part of manufacturing deal
AGC Biologics, a contract development and manufacturing organization (CDMO), has struck a partnership with BioNTech SE to further supply plasmid DNA (pDNA) starting material for the Pfizer-BioNTech Covid-19 vaccine, at AGC’s Heidelberg, Germany, facility.
“We are honored that BioNTech has entrusted us to become part of their global supply network in an effort to make the vaccine available to as many people as possible around the world,” says AGC Biologics Chief Business Officer Mark Womack. “We are very proud of our efforts to provide our global customers with the essential materials needed to rapidly deliver vaccines in the fight against the Covid-19 pandemic.”
AGC Biologics will manufacture and supply BioNTech with pDNA starting material, an essential component of BioNTech’s mRNA-based vaccine manufacturing process.
